NASDAQ:CDAKQ

Codiak BioSciences (CDAKQ) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.0016
$0.0016
50-Day Range
N/A
52-Week Range
$0.00
$3.26
Volume
N/A
Average Volume
905,289 shs
Market Capitalization
$58,928.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Codiak BioSciences

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. On March 27, 2023, Codiak BioSciences, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

CDAKQ Stock News Headlines

See More Headlines
Receive CDAKQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codiak BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:CDAKQ
Fax
N/A
Employees
102
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$22.93 million
Book Value
$2.39 per share

Miscellaneous

Free Float
33,810,000
Market Cap
$58,928.00
Optionable
Optionable
Beta
3.43
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Sriram Sathyanarayanan Ph.D. (Age 51)
    Chief Scientific Officer
    Comp: $502.17k
  • Ms. Linda Cathavina Bain CPA (Age 53)
    Treasurer
    Comp: $602.54k
  • Mr. Christopher J. M. Taylor
    VP of Investor Relations & Corp. Communications
  • Ms. Nicole Barna (Age 49)
    Sr. VP of HR

This page (NASDAQ:CDAKQ) was last updated on 5/10/2024 by MarketBeat.com Staff

From Our Partners